Skip to main content
logo
Kezar Life Sciences, Inc. (KZR)
May 11, 2026 - KZR was delisted (reason: acquired by AUPH)
7.29
0.00 (0.00%)
Inactive · Last trade price on May 8, 2026

Kezar Life Sciences Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
---7--
Revenue Growth
------
Gross Profit
---7--
Operating Income
-48.84-59.11-90.61-111.42-71.16-54.66
Net Income
-45.23-56.03-83.74-101.87-68.24-54.63
Earnings Per Share
-6.17-7.66-11.49-14.04-10.13-10.40
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
66.2371.88132.25201.37276.56208.36
Total Debt
1.352.3316.1818.9321.2614.04
Net Cash (Debt)
64.8869.55116.07182.44255.3194.31
Net Cash Growth
-35.29%-40.08%-36.38%-28.54%31.39%43.95%
Net Cash Per Share
8.859.5115.9225.1537.9036.83

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-42.03-51.78-74.21-81.65-58.85-42.44
Capital Expenditures
0-0.01-0.03-1.81-1.58-0.32
Free Cash Flow
-42.03-51.79-74.24-83.46-60.42-42.75
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
---100.00%--
Operating Margin
----1591.77%--
Pretax Margin
----1455.29%--
Profit Margin
----1455.29%--
FCF Margin
----1192.21%--

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
---98.46--